Anavex Life Sciences’ (AVXL) “Buy” Rating Reiterated at D. Boral Capital

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a research note issued on Monday,Benzinga reports. They presently have a $46.00 price objective on the biotechnology company’s stock. D. Boral Capital’s price objective suggests a potential upside of 339.35% from the stock’s current price.

Separately, HC Wainwright lifted their price target on Anavex Life Sciences from $40.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, December 26th.

Anavex Life Sciences Trading Down 0.8 %

AVXL stock opened at $10.47 on Monday. The firm has a 50-day moving average of $9.55 and a two-hundred day moving average of $7.06. The firm has a market capitalization of $888.02 million, a PE ratio of -20.94 and a beta of 0.70. Anavex Life Sciences has a one year low of $3.25 and a one year high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03. On average, equities research analysts anticipate that Anavex Life Sciences will post -0.55 earnings per share for the current year.

Institutional Investors Weigh In On Anavex Life Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Orion Capital Management LLC increased its stake in shares of Anavex Life Sciences by 666.7% in the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 10,000 shares during the last quarter. PVG Asset Management Corp acquired a new position in Anavex Life Sciences in the 3rd quarter worth about $74,000. Atria Investments Inc purchased a new stake in shares of Anavex Life Sciences during the 3rd quarter worth about $76,000. BNP Paribas Financial Markets lifted its holdings in shares of Anavex Life Sciences by 97.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock valued at $86,000 after buying an additional 7,421 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Anavex Life Sciences by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 6,366 shares in the last quarter. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.